目的探讨中期因子(midkine,MK)在人乳腺癌MDA-MB-231细胞体外血管生成中的作用及其机制。方法采用shRNA干扰技术降低MDA-MB-231细胞MK表达,应用Western blot技术检测肿瘤细胞中内皮蛋白C受体(endothelial protein C receptor,EPCR)的表...目的探讨中期因子(midkine,MK)在人乳腺癌MDA-MB-231细胞体外血管生成中的作用及其机制。方法采用shRNA干扰技术降低MDA-MB-231细胞MK表达,应用Western blot技术检测肿瘤细胞中内皮蛋白C受体(endothelial protein C receptor,EPCR)的表达;干扰MK和EPCR表达或通过抗体阻断活化蛋白酶激活受体1(protease-activated receptor 1,PAR1)作用后,制备肿瘤条件培养基作用于人脐静脉内皮细胞(human umbilical vein endothelial cells,HUVECs),通过CCK-8试剂盒检测HUVECs增殖、Transwell小室检测迁移以及Matrigel表面培养检测脉管形成能力。结果干扰MK表达后,EPCR表达随之降低。干扰MK和EPCR低表达后,HUVECs增殖、迁移及脉管形成能力均低于对照组(P<0.05),EPCR干扰组低于MK干扰组(P<0.05)。应用抗PAR1作用后,HUVECs增殖、迁移及脉管形成能力低于对照组和EPCR干扰组(P<0.05)。结论 MK可通过EPCR/PAR1通路促进乳腺癌MDA-MB-231细胞体外血管生成。展开更多
2024年7月12日,浙江大学基础医学院张岩/毛春友教授团队联合上海药物研究所徐华强团队在《细胞研究》(Cell Research)上发表了题为“Structural basis of tethered agonism and G protein coupling of protease-activated receptor”的...2024年7月12日,浙江大学基础医学院张岩/毛春友教授团队联合上海药物研究所徐华强团队在《细胞研究》(Cell Research)上发表了题为“Structural basis of tethered agonism and G protein coupling of protease-activated receptor”的研究论文(DOI:10.1038/s41422-024-00997-2),报道了人源PAR1独特的栓配体结合激活机制和G蛋白选择性机制,为开发新型靶向蛋白酶激活受体(PAR)1的G蛋白选择性药物提供了结构基础。展开更多
Whitmania pigra has been used as a traditional Chinese medicine(TCM) for promoting blood circulation, alleviating blood coagulation, activating meridians and relieving stasis for several hundred years. However, the th...Whitmania pigra has been used as a traditional Chinese medicine(TCM) for promoting blood circulation, alleviating blood coagulation, activating meridians and relieving stasis for several hundred years. However, the therapeutic components of this species, especially proteins and peptides were poorly exploited. Until now only a few of them were obtained by using chromatographic isolation and purification. In recent decade, transcriptome techniques were rapidly developed, and have been used to fully reveal the functional components of many animal venoms. In the present study, the c DNA of the salivary gland of Whitmania pigra was sequenced by illumina and the transcriptome was assembled by using Trinity. The proteome were analysed by LC-MS/MS. Based on the data of the transcriptome and the proteome, a potential antiplatelet protein named pigrin was found. Pigrin was cloned and expressed using P. pastoris GS115. The antiplatelet and antithrombotic bioactivities of pigrin were tested by using aggregometer and the rat arterio-venous shunt thrombosis model, respectively. The bleeding time of pigrin was measured by a mice tail cutting method. The docking of pigrin and protease-activated receptor 1(PAR1) or collagen were conducted using the ZDOCK Server. Pigrin was able to selectively inhibit platelet aggregation stimulated by PAR1 agonist and collagen. Pigrin attenuated thrombotic formation in vivo in rat, while did not prolong bleeding time at its effective dosage. There are significant differences in the key residues participating in binding of Pigrin-Collagen complex from Pigrin-PAR1 complex. In conclusion, a novel PAR1 inhibitor pigrin was found from the leech Whitmania pigra. This study helped to elucidate the mechanism of the leech for the treatment of cardiovascular disorder.展开更多
文摘2024年7月12日,浙江大学基础医学院张岩/毛春友教授团队联合上海药物研究所徐华强团队在《细胞研究》(Cell Research)上发表了题为“Structural basis of tethered agonism and G protein coupling of protease-activated receptor”的研究论文(DOI:10.1038/s41422-024-00997-2),报道了人源PAR1独特的栓配体结合激活机制和G蛋白选择性机制,为开发新型靶向蛋白酶激活受体(PAR)1的G蛋白选择性药物提供了结构基础。
基金supported by China Pharmaceutical University initiative program(No.CPU2018GY15)the National Natural Science Foundation for Young Scientists of China(No.81603647)
文摘Whitmania pigra has been used as a traditional Chinese medicine(TCM) for promoting blood circulation, alleviating blood coagulation, activating meridians and relieving stasis for several hundred years. However, the therapeutic components of this species, especially proteins and peptides were poorly exploited. Until now only a few of them were obtained by using chromatographic isolation and purification. In recent decade, transcriptome techniques were rapidly developed, and have been used to fully reveal the functional components of many animal venoms. In the present study, the c DNA of the salivary gland of Whitmania pigra was sequenced by illumina and the transcriptome was assembled by using Trinity. The proteome were analysed by LC-MS/MS. Based on the data of the transcriptome and the proteome, a potential antiplatelet protein named pigrin was found. Pigrin was cloned and expressed using P. pastoris GS115. The antiplatelet and antithrombotic bioactivities of pigrin were tested by using aggregometer and the rat arterio-venous shunt thrombosis model, respectively. The bleeding time of pigrin was measured by a mice tail cutting method. The docking of pigrin and protease-activated receptor 1(PAR1) or collagen were conducted using the ZDOCK Server. Pigrin was able to selectively inhibit platelet aggregation stimulated by PAR1 agonist and collagen. Pigrin attenuated thrombotic formation in vivo in rat, while did not prolong bleeding time at its effective dosage. There are significant differences in the key residues participating in binding of Pigrin-Collagen complex from Pigrin-PAR1 complex. In conclusion, a novel PAR1 inhibitor pigrin was found from the leech Whitmania pigra. This study helped to elucidate the mechanism of the leech for the treatment of cardiovascular disorder.
